Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Rhea-AI Summary

INOVIO (NASDAQ:INO) announced that it will present immunological activity data for INO-3107 at the American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology conference, scheduled for February 23-26, 2025. The poster presentation will focus on the loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following INO-3107 treatment, specifically highlighting the induction of emergent T cells in patients who showed durable complete clinical response. The abstract will be made available on INOVIO's website after the conference.

Positive

• Clinical data shows complete response in RRP patients treated with INO-3107
• Evidence of HPV-6 elimination in treated patients
• Successful T cell induction demonstrated by the treatment

Negative

• None.

News Market Reaction

-2.04%

1 alert

-2.04% News Effect

On the day this news was published, INO declined 2.04%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107

PLYMOUTH MEETING, Pa., Feb. 10, 2025 /PRNewswire/ --  INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference:

American Association for Cancer Research – Immuno-Oncology
Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025)
Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107"

The abstract will be made available on INOVIO's website following the conference.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations@inovio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/immune-response-data-for-ino-3107-to-be-presented-as-a-poster-at-american-association-for-cancer-research-immuno-oncology-aacr-io-conference-302372309.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What are the key findings of INO-3107 treatment in RRP patients presented at AACR-IO 2025?

The findings show loss of detectable HPV-6 following induction of emergent T cells in patients who achieved durable complete clinical response to INO-3107 treatment for Recurrent Respiratory Papillomatosis.

When will INOVIO present the INO-3107 immunological data at AACR-IO conference?

INOVIO will present the INO-3107 data at the AACR-IO conference taking place from February 23-26, 2025.

What is the significance of HPV-6 elimination in INO-3107 treated patients?

The elimination of detectable HPV-6 following INO-3107 treatment indicates the therapy's effectiveness in treating Recurrent Respiratory Papillomatosis through immune response activation.

How can investors access the INO-3107 abstract presented at AACR-IO 2025?

The abstract will be made available on INOVIO's website following the conference's conclusion.